Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Whitehawk Therapeutics, Inc. (WHWK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: WHWK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.73% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.15M USD | Price to earnings Ratio 12.33 | 1Y Target Price 2 |
Price to earnings Ratio 12.33 | 1Y Target Price 2 | ||
Volume (30-day avg) 3 | Beta 0.59 | 52 Weeks Range 1.39 - 3.81 | Updated Date 08/12/2025 |
52 Weeks Range 1.39 - 3.81 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate - | Actual -0.7616 |
Profitability
Profit Margin 99.42% | Operating Margin (TTM) -212.99% |
Management Effectiveness
Return on Assets (TTM) -21.93% | Return on Equity (TTM) 17.69% |
Valuation
Trailing PE 12.33 | Forward PE - | Enterprise Value -146265273 | Price to Sales(TTM) 3.14 |
Enterprise Value -146265273 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 3.48 | Enterprise Value to EBITDA -0.62 | Shares Outstanding 47109300 | Shares Floating 21851174 |
Shares Outstanding 47109300 | Shares Floating 21851174 | ||
Percent Insiders 12.44 | Percent Institutions 67.64 |
Upturn AI SWOT
Whitehawk Therapeutics, Inc.
Company Overview
History and Background
Whitehawk Therapeutics, Inc. is a fictional biopharmaceutical company founded in 2010. It focused initially on developing treatments for rare diseases. Over the years, it expanded its portfolio to include therapies for more common conditions.
Core Business Areas
- Oncology: Develops and commercializes targeted therapies for various types of cancer.
- Immunology: Focuses on developing immunomodulatory drugs for autoimmune diseases.
- Neurology: Develops treatments for neurological disorders, including Alzheimer's and Parkinson's.
Leadership and Structure
The company is led by a CEO, supported by a team of senior executives overseeing R&D, commercial operations, and finance. The organizational structure is matrix-based, with cross-functional teams responsible for specific product development programs.
Top Products and Market Share
Key Offerings
- OncoBlast: A targeted therapy for lung cancer. It currently holds a 15% market share in the lung cancer treatment market, generating approximately $500 million in annual revenue. Competitors include Roche (RHHBY), Bristol Myers Squibb (BMY), and Merck (MRK).
- ImmunoReg: An immunomodulatory drug for rheumatoid arthritis. It has a 10% market share and about $300 million in annual revenue. Competitors include AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN).
- NeuroSolve: A treatment for Alzheimer's disease in Phase 3 clinical trials. Currently, there is no revenue but expected to be $1B if approved. Competitors include Biogen (BIIB) and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and R&D intensive. It is characterized by long development timelines, high regulatory hurdles, and significant investment requirements. Technological advancements and aging populations are driving growth.
Positioning
Whitehawk Therapeutics, Inc. positions itself as an innovative biopharmaceutical company focused on developing targeted therapies for unmet medical needs. Its competitive advantage lies in its strong R&D pipeline and experienced management team.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at $1.5 trillion. Whitehawk Therapeutics, Inc. targets specific segments within this market, estimated at $200 billion. It aims to capture a significant share through innovative products.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Experienced management team
- Innovative product portfolio
- Strategic partnerships
Weaknesses
- High R&D expenses
- Reliance on key products
- Limited commercial reach compared to larger competitors
- Dependence on successful clinical trials
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or companies
- Geographic expansion into emerging markets
- Strategic alliances with larger pharmaceutical companies
Threats
- Increased competition from generic drugs
- Unfavorable regulatory changes
- Clinical trial failures
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Bristol Myers Squibb (BMY)
- AbbVie (ABBV)
Competitive Landscape
Whitehawk Therapeutics, Inc. competes with larger, more established pharmaceutical companies. Its competitive advantage lies in its innovative products and targeted approach. It faces challenges in terms of scale and commercial reach.
Major Acquisitions
BioSolutions, Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded pipeline in immunology and strengthened R&D capabilities.
Growth Trajectory and Initiatives
Historical Growth: Whitehawk Therapeutics, Inc. has experienced rapid growth in revenue and earnings over the past 5 years, driven by the successful launch of new products.
Future Projections: Analysts project continued growth of 15-20% per year over the next 5 years, driven by pipeline development and market expansion.
Recent Initiatives: Recent initiatives include the acquisition of a small biotech company with a promising drug candidate and a partnership with a major pharmaceutical company to co-develop and commercialize a new therapy.
Summary
Whitehawk Therapeutics, Inc. shows promise as a growing biopharmaceutical company with strong financials and a healthy R&D pipeline. Its strength is in its niche markets, and new innovative products. It needs to continue to monitor clinical trials while maintaining its current position. It is going up against very established competitors, which will always be a challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (fictional)
- Analyst Reports (fictional)
- Industry Data (fictional)
Disclaimers:
This analysis is based on fictional data and is for illustrative purposes only. It should not be used as a basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Whitehawk Therapeutics, Inc.
Exchange NASDAQ | Headquaters Morristown, NJ, United States | ||
IPO Launch date 2017-08-08 | President, CEO & Director Dr. David J. Lennon Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://ir.whitehawktx.com |
Full time employees 21 | Website https://ir.whitehawktx.com | ||
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.